PARSIPPANY, N.J., March 8 /PRNewswire/ -- The U.S. infertility specialty has empirically incorporated greater amounts of human menopausal gonadotropin (hMG) into stimulation protocols, according to a new review article, “Gonadotropins in the Treatment of Infertility” by George T. Koulianos, MD, published in a recent issue of US Obstetrics & Gynecology, supported by an educational grant from Ferring Pharmaceuticals.(1) The article reviews the wealth of clinical evidence supporting this trend, and demonstrates how the use of gonadotropins in the treatment of infertility, especially in assisted reproductive technologies, has significantly improved outcomes.
“Gonadotropins...have been especially important in improving the efficiency of in vitro fertilization,” said Dr. Koulianos. “The many large, complex studies conducted over the past decade demonstrate the unique attributes of hMG, especially highly purified hMG, that lead to better outcomes. The study results parallel the steady increase in the use of hMG, indicating that the field has empirically chosen hMG as its base of stimulation.”
Here are highlights from the article:
Odds Ratios Showing the Effect of hMG and rFSH on Live Birth Rate*
OR=odds ratio; CI=confidence interval; df=degrees of freedom; Z=vector of other variables
*Chart adapted from Figure 7 in the review article
About MENOPUR(R)
MENOPUR(R) administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program.
Important Safety Information
Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe MENOPUR(R). MENOPUR(R) is a potent substance capable of causing mild to severe adverse reactions, including OHSS (overall incidence 3.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. MENOPUR(R) is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; sex hormone dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins or MENOPUR(R). MENOPUR(R) is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.
Please visit www.ferringfertility.com for Full Prescribing Information for MENOPUR(R).
Footnotes
CONTACT: Andrea Preston, Kovak-Likly Communications, +1-203-762-8833,
apreston@klcpr.com
Web site: http://www.ferringfertility.com/
